This company listing is no longer active
IM Cannabis (IMCC) Stock Overview
Engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IMCC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
IM Cannabis Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$5.10 |
| 52 Week High | CA$9.70 |
| 52 Week Low | CA$1.75 |
| Beta | 3.17 |
| 1 Month Change | 131.82% |
| 3 Month Change | 91.73% |
| 1 Year Change | 32.81% |
| 3 Year Change | -91.67% |
| 5 Year Change | -97.88% |
| Change since IPO | -96.63% |
Recent News & Updates
Recent updates
A Piece Of The Puzzle Missing From IM Cannabis Corp.'s (CSE:IMCC) Share Price
Mar 05
Slammed 28% IM Cannabis Corp. (CSE:IMCC) Screens Well Here But There Might Be A Catch
Sep 13A Piece Of The Puzzle Missing From IM Cannabis Corp.'s (CSE:IMCC) Share Price
Jul 30Potential Upside For IM Cannabis Corp. (CSE:IMCC) Not Without Risk
Jul 19Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?
Dec 24Don't Ignore The Fact That This Insider Just Sold Some Shares In IM Cannabis Corp. (CSE:IMCC)
Feb 05
What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?
Jan 08Shareholder Returns
| IMCC | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 0.08% |
| 1Y | 32.8% | 9.0% | 30.8% |
Return vs Industry: IMCC exceeded the Canadian Pharmaceuticals industry which returned -57.4% over the past year.
Return vs Market: IMCC exceeded the Canadian Market which returned 15.6% over the past year.
Price Volatility
| IMCC volatility | |
|---|---|
| IMCC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 14.1% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in CA Market | 19.5% |
| 10% least volatile stocks in CA Market | 3.4% |
Stable Share Price: IMCC's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine IMCC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 95 | Oren Shuster | imcannabis.com |
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It provides medical cannabis dried flowers; and cannabis extracts under the IMC, BLKMT, WAGNERS, and LOT420 brands. The company serves medical patients.
IM Cannabis Corp. Fundamentals Summary
| IMCC fundamental statistics | |
|---|---|
| Market cap | CA$8.18m |
| Earnings (TTM) | -CA$4.69m |
| Revenue (TTM) | CA$54.47m |
Is IMCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMCC income statement (TTM) | |
|---|---|
| Revenue | CA$54.47m |
| Cost of Revenue | CA$44.35m |
| Gross Profit | CA$10.12m |
| Other Expenses | CA$14.81m |
| Earnings | -CA$4.69m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 18.58% |
| Net Profit Margin | -8.61% |
| Debt/Equity Ratio | 481.3% |
How did IMCC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/10 10:50 |
| End of Day Share Price | 2025/06/02 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IM Cannabis Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |